Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,087 recruiting studies in this area right now.
By phase
- Not applicable2,108
- Phase 21,118
- Phase 1824
- Phase 1/Phase 2483
- Phase 3349
- Phase 4127
- Phase 2/Phase 378
Top conditions
- Multiple Myeloma332
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease140
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia123
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema49
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center65
- City of Hope Medical Center61
- Mayo Clinic61
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California405
- Texas186
- Maryland149
- Alabama148
- Arizona124
- Florida111
- Massachusetts101
- New York98
- Ohio70
- Minnesota68
Recruiting studies5,087 total
- NCT04883437RecruitingPhase 2
Acalabrutinib plus obinutuzumab for slow-growing lymphoma
This Phase 2 study tests two medicines together—acalabrutinib and obinutuzumab—in people with previously untreated, slow-growing B-cell lymphomas. It aims to shrink the lymphoma and improve disease control, especially when tumor burden is low or when standard first treatments aren’t suitable.
Atlanta, GeorgiaAges 18 years+ - NCT04888039Recruiting
Living with myeloma follow-up study in West-Occitanie
This study follows people with symptomatic multiple myeloma who live in the West-Occitanie region. It aims to better understand patients’ experiences and needs over time, which may help improve care and support.
Toulouse, West-OccitanieAges 18 years+ - NCT04888338Recruiting
Studying outcomes after CAR-T, radiation, or bispecific therapy
This study looks at how people with blood cancers do after they receive CAR-T therapy, radiation therapy, and/or bispecific therapy. It may help doctors understand which treatment combinations work best and what side effects to expect.
Houston, TexasAges 18 years+ - NCT04888975Recruiting
Device study for one-arm swelling after lymph surgery
This study tests a medical device (Dayspring Technology) to reduce swelling in the arm caused by breast cancer treatment and lymph surgery. You may be eligible if you have one-sided arm swelling after lymphatic surgery and meet safety checks for the device.
Palo Alto, CaliforniaAges 18 years+ - NCT04888741RecruitingPhase 2
Trial testing reduced immune T cells before stem cell transplant
This Phase 2 trial looks at a transplant approach that reduces harmful immune cells (T cells) before or during an allogeneic stem cell transplant. It may help lower the risk of transplant complications while still letting the donor immune system fight the blood cancer.
Cardiff, WalesAges 16–70 - NCT04889716RecruitingPhase 2
CAR-T followed by antibody treatment for lymphoma
This Phase 2 study looks at giving CAR-T cell therapy first, then follow-up “bispecific” antibody medicines to help keep large B-cell lymphoma from coming back. It’s for people whose lymphoma returned or did not respond to prior standard treatments and who still have measurable disease on scans.
Omaha, NebraskaAges 18 years+ - NCT04892277RecruitingPhase 1
CD19 CAR-T for adults with hard-to-treat B-cell cancers
This Phase 1 trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell cancers have come back or did not respond to treatment. It may help your immune system better recognize and attack cancer cells, but it is early research, so benefits and risks are still being defined.
Rochester, MinnesotaAges 18 years+ - NCT04893564Recruiting
Testing blood DNA after 6 months of Waldenström treatment
This study looks at a blood test called circulating tumor DNA, measured after 6 months of treatment, to see how well it predicts outcomes in people with Waldenström macroglobulinemia. It may help doctors better judge who is responding and who may need treatment adjustments earlier.
AmiensAges 18 years+ - NCT04895436RecruitingPhase 2
Oral venetoclax plus IV obinutuzumab after prior CLL treatment
This trial tests whether adding oral venetoclax together with an IV antibody called obinutuzumab can control CLL when the disease comes back after a specific prior treatment. It also looks closely at side effects to see what changes in “disease activity” and safety to expect.
La Jolla, CaliforniaAges 18 years+ - NCT04897490Recruiting
Real-world study of ATO plus ATRA for adult acute APL
This study looks at how well first-time treatment with ATO plus ATRA works in adults with acute promyelocytic leukemia (APL). It mainly checks treatment results in real life, including whether patients reach “molecular remission” (very deep disease control).
La Plata, Buenos AiresAges 18 years+ - NCT04898647Recruiting
Study of blood thickness in Waldenström’s disease
This study looks at “hyperviscosity,” meaning very thick blood, in people with Waldenström macroglobulinemia (WM). Your results may help doctors better understand who needs treatment and what tests should be used, even if thick blood is not found.
AmiensAges 18 years+ - NCT04898790Recruiting
Testing ways to improve thinking after bone marrow transplant
This study looks at whether a physical activity program and related study measures can improve thinking and memory in older adults around the time of a stem cell transplant. If you qualify and participate, the team will compare outcomes between groups to see what approach works best.
Omaha, NebraskaAges 19 years+ - NCT04901936RecruitingPhase 2
Study of pegcetacoplan for kids with PNH blood problems
This trial tests pegcetacoplan in children (ages 12–17) with paroxysmal nocturnal hemoglobinuria (PNH), a condition that can cause ongoing blood cell breakdown. The goal is to see if the medicine can improve anemia related to PNH.
Atlanta, GeorgiaAges 12–17 - NCT04902807Recruiting
Tool to help decide diagnosis and treatment in immune disorders
This trial tests a tool (a way of collecting health information) to help doctors make better diagnosis, prognosis, and treatment decisions for children with certain immune problems. It also includes healthy children (like relatives) as comparison groups, to see how well the tool works.
ParisAges 1–18 - NCT04904146Recruiting
Testing blood or tumor markers in skin lymphoma patients
This study looks for “predictive” and “prognostic” biomarkers—measurable signs in blood or tissue—to help predict how mycosis fungoides or Sézary syndrome will behave and how patients may respond to care. It may help doctors better understand outcomes for people with these skin lymphomas.
LundAges 18–100 - NCT04905810RecruitingPhase 2
Azacitidine or decitabine plus venetoclax for AML after prior failure
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
Clovis, CaliforniaAges 18 years+ - NCT04908228RecruitingPhase 2
Fixed treatment with ibrutinib and obinutuzumab for untreated CLL
This Phase 2 study tests a fixed-length treatment plan using ibrutinib plus obinutuzumab for people with newly diagnosed, active CLL/SLL that needs treatment. It may help control the leukemia/lymphoma by combining a targeted drug with an antibody therapy.
Milan, MIAges 18 years+ - NCT04913649RecruitingPhase 4
IV iron for anemia after heart surgery in older adults
This trial tests whether giving iron through a vein after heart surgery helps treat postoperative anemia (low red blood cells) in people age 70 and older. It may improve recovery by correcting low iron levels after surgery.
BredaAges 70 years+ - NCT04915248RecruitingPhase 2
Study of daratumumab, bortezomib, and dexamethasone for plasmablastic lymphoma
This trial tests how well a combination of daratumumab, bortezomib, and dexamethasone works in people with plasmablastic lymphoma that has returned or did not respond to prior treatment. It aims to shrink measurable tumors and improve outcomes, including for some people living with HIV.
AnconaAges 18 years+ - NCT04920617RecruitingPhase 2
Vaccine plus pembrolizumab, with or without low-dose chemo
This Phase 2 study tests whether a cancer vaccine called DPX-Survivac, along with pembrolizumab (an immune medicine), can help shrink diffuse large B-cell lymphoma (DLBCL) that has come back or not responded. It also looks at whether adding intermittent low-dose cyclophosphamide (a low-dose chemotherapy) improves results.
Fountain Valley, CaliforniaAges 18 years+ - NCT04922567RecruitingPhase 2
Lenalidomide plus CHOP versus CHOP for untreated PTCL
This Phase 2 trial compares two chemotherapy approaches—adding lenalidomide to CHOP versus CHOP alone—for people with untreated peripheral T-cell lymphoma (PTCL). The goal is to see if the added medicine improves response and safety.
Hangzhou, ZhejiangAges 18–75 - NCT04925609RecruitingPhase 1/Phase 2
Brigatinib for young people with ALK-positive cancer
This trial tests brigatinib, a targeted pill medicine, in children and young adults with ALK-positive cancers (including ALCL and IMT, plus some other solid tumors). It’s designed to see how well it works and what side effects it causes in people whose tumors have a specific ALK change.
ParisAges 1–25 - NCT04929899Recruiting
Test of a learning tool during leukemia maintenance
This study checks whether a tablet-based tool (called PeNAT) can be used by children during the usual maintenance treatment phase for ALL (a type of leukemia). It may help families and clinicians better support care at home or during follow-up by testing how well the tool works in real patients.
Los Angeles, CaliforniaAges 4–18 - NCT05735717RecruitingPhase 2
T-cell transplant using depleted receptors for blood cancers
This Phase 2 study tests a specialized stem cell transplant that removes certain immune “T-cell” receptors to help treat blood cancers like acute leukemia. It may help your body rebuild a healthier immune system after high-dose treatment.
Minneapolis, MinnesotaAges Up to 60 years
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,087 recruiting hematology studies from the U.S. registry right now, out of 7,715 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.